Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with...

Read More

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Read More

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Read More

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the effects of enzalutamide on the health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Jan 30, 2022 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effects on the health-related quality of life (HR-QoL) of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide preserved the overall health and quality of life in these...

Read More

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Read More

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Nov 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...

Read More

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Sep 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...

Read More

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More

Searching for patients with advanced prostate cancer to trial an immunotherapy

Searching for patients with advanced prostate cancer to trial an immunotherapy

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...

Read More

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the impact of the pattern of metastatic spread on the effectiveness of enzalutamide in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that the combination has good outcomes in men with bone and/or lymph node...

Read More

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study was carried out to look at the use of combining radiotherapy (RT), systemic therapy (ST; whole-body treatment), and androgen deprivation therapy (ADT) for prostate cancer (PC) that is hormone-sensitive and has spread. The authors concluded that ADT plus RT led to better outcomes in patients with low-volume disease. Some...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor